Citrine to Bring Treatment for Narcolepsy, a Rare Disease, to China

Citrine Medicine, a Shanghai rare disease startup, in-licensed China rights to a marketed treatment for narcolepsy and obstructive sleep apnea from Bioprojet SCR of Paris. In June, Citrine completed an $80 million Series A round led by Quan Capital to acquire products that address unmet needs for rare diseases. Citrine plans to develop a rare disease ecosystem that includes information, diagnosis and therapeutics. The company will have exclusive China rights to develop, market and manufacture Bioprojet's Wakix (pitolisant). Citrine was co-founded by Eight Roads, F-Prime Capital and Vivo Capital. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.